The antitumor activity of recombinant human lymphotoxin
LI Chun yi1,REN Wen long2,LI Chang ben3,et al.1.Department of Clinical Pharmjacology,Beijing Institute for Cancer Research, Beijing 100034,P.R.China2.Department of Pharmacology,Shanghai Institute of Pharmaceutical Industry,Shanghai 200437,P.R.China3.Th
Objective:To investigate the antitumor activity in vitro and in vivo of recombinant human lymphotoxin(rhLT).Methods:Cytotoxicity was measured using MTT assay.The antitumor activity in vivo was evaluated by transplanted mouse solid tumor.Results:(1) In vitro rhLT showed cytotoxicity on human gastric carcinomas MKN 45,the IC50 was 1.98×10 2μg/ml.(2) In vivo rhLT had a significant antitumor effect on mouse solid tumors (sarcoma 180 Ehrlich carcinoma),the rate of inhibition were 34.13%and 34.08%, respectively.(3) In the experimental pulmonary metastasis model induced by i.v. injection of mouse B16 melanoma, a high preventive and curative effect of rhLT was obtained by systemic administration in syngenic mice, the rate of inhibition were:preventive group,30.61%;treatment group, 59.45%;preventive treatment group,79.23%;respectively. Conclusion:RhLT has a significant antitumor effect on human gastric carcimoma MKN 45 in vitro and murine solid tumor in vivo, and has a potent preventive effect on metastasis.
【CateGory Index】： R730.53